stockrowNovartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −69.1%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
Follow NVS
Alert me
Novartis AG (NVS) Operating cash flow
Novartis AG's operating cash flow for fiscal 2025 was $19.1B, up 8.66% from $17.6B in fiscal 2024. Over the twelve months to 30 September 2026 it was $17.3B. Over the past ten years it has ranged from $11.5B (fiscal 2016) to $19.1B (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 3 consecutive fiscal years. Novartis AG ranks 7th of 21 Drug Manufacturers General companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $19.1B | 8.66% |
| FY2024 | $17.6B | 21.86% |
| FY2023 | $14.5B | 1.56% |
| FY2022 | $14.2B | (5.54%) |
| FY2021 | $15.1B | 10.41% |
| FY2020 | $13.7B | 0.18% |
| FY2019 | $13.6B | (4.53%) |
| FY2018 | $14.3B | 13.08% |
| FY2017 | $12.6B | 9.99% |
| FY2016 | $11.5B | (3.55%) |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $5.5B | (6.44%) |
| Jun 2026 | $5.9B | 60.01% |
| Mar 2026 | $3.7B | 62.37% |
| Dec 2025 | $2.3B | (65.55%) |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| JNJ Johnson & Johnson compare | $26.2B |
| NVO Novo Nordisk A/S compare | $20.4B |
| ABBV AbbVie Inc. compare | $20.1B |
| MRK Merck & Co., Inc. compare | $20.0B |
| NVS Novartis AG | $17.3B |
| GILD Gilead Sciences, Inc. compare | $14.5B |
| PFE Pfizer Inc. compare | $14.2B |
| AZN AstraZeneca PLC compare | $13.2B |
| AMGN Amgen Inc. compare | $12.0B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on NVS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement